HealthTree Logo
search more_vert
App Logo
person Sign In / Create Account
Gilead Drops Kite Multiple Myeloma CAR T Development
Posted: Feb 12, 2019
Gilead Drops Kite Multiple Myeloma CAR T Development image

Gilead released fourth quarter results that removed an anti-BCMA cell therapy for multiple myeloma from it's pipeline, part of its $12 billion acquisition of Kite Pharma.

The decision to drop the KITE-585-CAR T programs indicates the ever growing competition in the BCMA-targeted therapy for myeloma and represents a loss of $820M in investment. 

Other anti-BCMA CAR T treatments are in development. At the recent ASH conference in San Diego, there were more than 10 different anti-BCMA regiments including CAR T therapies, bi-specific antibodies and antibody-drug conjugates. These approaches come from Celgene, Novartis, Janssen, Amgen, GSK and others.  In addition, some major myeloma academic centers are also testing the manufacturing of their own CAR T therapy in-house, making the field even more crowded. 

Not all CAR T therapies are the same and at this time, it is uncertain which CAR T will provide the best deepest and longest benefit to patients. 

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Bristol Myers Squibb

Follow Us

facebook instagram twitter youtube